These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 32680651

  • 1. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
    Tian C, Wong BL, Hornung L, Khoury JC, Rybalsky I, Shellenbarger KC, Rutter MM.
    Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
    [Abstract] [Full Text] [Related]

  • 2. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C, Wong BL, Hornung L, Khoury JC, Miller L, Bange J, Rybalsky I, Rutter MM.
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [Abstract] [Full Text] [Related]

  • 3. The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid-induced osteoporosis.
    Nasomyont N, Tian C, Hornung L, Khoury J, Hochwalt PM, Tilden JC, Wong BL, Rutter MM.
    Muscle Nerve; 2021 Dec; 64(6):710-716. PubMed ID: 34506040
    [Abstract] [Full Text] [Related]

  • 4. Bone density and alendronate effects in Duchenne muscular dystrophy patients.
    Houston C, Mathews K, Shibli-Rahhal A.
    Muscle Nerve; 2014 Apr; 49(4):506-11. PubMed ID: 23835890
    [Abstract] [Full Text] [Related]

  • 5. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
    Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan HJ, Matzinger MA, Ward LM.
    Osteoporos Int; 2012 Nov; 23(11):2703-11. PubMed ID: 22297733
    [Abstract] [Full Text] [Related]

  • 6. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K, McAdam L, Ma J, McMillan HJ, Jackowski S, Scharke M, Matzinger MA, Shenouda N, Koujok K, Jaremko JL, Smit K, Walker S, Hartigan C, Khan N, Konji VN, MacLeay L, Page M, Sykes E, Robinson ME, Alos N, Cummings EA, Ho J, Sbrocchi AM, Stein R, Saleh D, Craven BC, Dang UJ, Siminoski K, Rauch F, Ward LM.
    Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
    [Abstract] [Full Text] [Related]

  • 7. Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
    Zheng WB, Dai Y, Hu J, Zhao DC, Wang O, Jiang Y, Xia WB, Xing XP, Li M.
    Endocr Pract; 2020 Dec; 26(12):1477-1485. PubMed ID: 33471740
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy.
    Nasomyont N, Keefe C, Tian C, Hornung L, Khoury J, Tilden JC, Hochwalt P, Jackson E, Rybalsky I, Wong BL, Rutter MM.
    Osteoporos Int; 2020 Dec; 31(12):2449-2459. PubMed ID: 32676823
    [Abstract] [Full Text] [Related]

  • 9. Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy.
    Apkon S, Coll J.
    Am J Phys Med Rehabil; 2008 Feb; 87(2):139-43. PubMed ID: 17912140
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A, Liguori S, Paoletta M, Gimigliano F, Iolascon G.
    Adv Ther; 2022 Jul; 39(7):3308-3315. PubMed ID: 35614293
    [Abstract] [Full Text] [Related]

  • 13. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
    Tamechika SY, Sasaki K, Hayami Y, Ohmura SI, Maeda S, Iwagaitsu S, Naniwa T.
    Arch Osteoporos; 2018 Jun 13; 13(1):67. PubMed ID: 29904824
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of Denosumab for Glucocorticoid-Induced Osteoporosis in an Adolescent Patient with Duchenne Muscular Dystrophy: A Case Report.
    Kumaki D, Nakamura Y, Sakai N, Kosho T, Nakamura A, Hirabayashi S, Suzuki T, Kamimura M, Kato H.
    JBJS Case Connect; 2018 Jun 13; 8(2):e22. PubMed ID: 29642113
    [Abstract] [Full Text] [Related]

  • 15. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.
    N Engl J Med; 2007 Nov 15; 357(20):2028-39. PubMed ID: 18003959
    [Abstract] [Full Text] [Related]

  • 16. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R, Reddy BVC, Malviya M, Sirari T, Attri SV, Patial A, Tageja M, Didwal G, Khandelwal NK, Saini AG, Saini L, Sahu JK, Dayal D, Sankhyan N.
    J Pediatr Endocrinol Metab; 2021 May 26; 34(5):573-581. PubMed ID: 33838091
    [Abstract] [Full Text] [Related]

  • 17. [Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy].
    Palomo Atance E, Ballester Herrera MJ, Márquez de La Plata MA, Medina Cano E, Carmona Vilchez RM.
    An Pediatr (Barc); 2011 Feb 26; 74(2):122-5. PubMed ID: 21169073
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.